- Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease
PR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018